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Twenty-three years after the discovery of the CFTR gene, more than 1900 anomalies
are described in the world, the majority of them being single base-pair substitutions
or micro-insertions/deletions. Identiﬁcation of mutations has important implications
for genetic counselling, prenatal diagnosis, cascade screening in families, as well
as for understanding the genotype–phenotype relationship.
Since a few years, NGS technologies enable us to overcome the classical approaches
of whole coding sequence sequencing at single nucleotide resolution.
The aim of our study is to compare 3 different strategies with the Ion Torrent
technology (Life Technologies, LT): Ampliseq (LT), Haloplex (Agilent) and home-
made Long Range PCR (LR).
Preliminary results showed that the coverage of the CFTR locus by Ampliseq is
limited to 51% and includes 86% of exons with a depth generally consistent between
amplicons. Haloplex approach gives more heterogeneous depth and coverage.
Finally, LR-PCR showed coverage consistent with the design but differences at
depth between each LR ampliﬁcation.
The development of libraries by the two ﬁrst approaches is rapid (less than 24 h)
and technically easy. For LR-PCR, It takes about two days to build a library with
long and time-consuming manual steps.
Sequencing result for the CFTR gene were validated with wild-type samples and
DNA carrying known variants (mutations and polymorphisms) previously identiﬁed
by DHPLC, HRM and sequencing.
In conclusion, the sequencing of the entire CFTR locus by NGS is a tool that
can quickly respond to issues such as prenatal diagnostic and the most promising
approach seems to be the LR strategy.
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Overall, multiplex analysis of common CF mutations facilitates the CF molecular
diagnostics; however, despite the availability of different commercial panels, the
high allelic heterogeneity of the CFTR gene (near 2000 mutations) makes still
difﬁcult the characterization of CF mutations, especially in those populations with
a wide mutational spectrum. Next Generation Sequencing (NGS) technologies
have proven a high sensitivity to detect sequence variants, irrespectively of their
frequency. Herein, we have assessed the suitability of this technology to be applied
in CF molecular diagnostics using a cohort of 30 CF patients well characterized.
In total, 48 mutations along the gene have been selected for this blind study,
considering common and rare mutations mainly, missense (n = 23), nonsense (n = 8),
in/dels (n = 2), frameshift (n = 4) and splicing (n = 11) mutations. Furthermore, the
cohort includes heterozygous and homozygous samples as well as some complex
alleles. Sequence capture was performed using the NimbleGen sequence capture
technology. On average, >99% of all targeted bases were covered by at least 5 reads
with a mean coverage achieved of 231X. Thus, the NGS sequencing data provided
an adequate depth of sequencing coverage to accurately detect the CFTR exome
variants. In fact, all CF mutations and different coding SNPs were successfully
identiﬁed. In conclusion, this pilot study supports that NGS technologies provide
precise and quick results and are ready to be implemented in routine genetic
diagnostics.
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Objectives: Molecular diagnosis of cystic ﬁbrosis and CFTR-RD led to the
worldwide identiﬁcation of nearly 2000 sequence variations in the CFTR gene.
To improve efﬁciency of current scanning methods, we evaluated in two French
laboratories the CFTR MASTR V2 kit designed to allow in a single condition
reaction the detection of point mutations, microinsertions/deletions in the 27 coding
and ﬂanking sequences, plus 3 deep intronic mutations and Copy Number Variations
(CNVs).
Methods: 39 samples heterozygous or compound heterozygous for 39 different
point mutations and 5 CNVs previously characterized by Sanger sequencing,
QMPSF or MLPA were re-analyzed on the Roche Junior NGS. The sizes of
amplicons were controlled by Genescan Analysis on an ABI platform using
GeneMapper software. Data was analyzed using AVA (Roche) and/or SeqNext
softwares (JSI Medical System).
On the 39 mutations, 33 were correctly identiﬁed; 3, located in exonic homopolymer
stretches, were indistinguishable by the software but were detected by GeneScan
on the basis of abnormal amplicon sizes; 3 were TGmTn mutations (intron 9) and
showed a correctly identiﬁed T5 repeat and an inexact TG repeat. Large deletions
were all identiﬁed but a high rate of false positives was observed; large duplications
were not tested.
Conclusion: This technique enables a rapid and high-performance analysis for the
determination of mutations. The results conﬁrm that homopolymer stretches are
the main limitation of pyrosequencing technologies and underline the importance
of the GeneScan control to limit the risk of false negatives in these regions. CNVs
detection requires optimization and further experiments.
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Objectives: Next generation sequencing (NGS) is a revolutionary technology that
delivers fast, inexpensive and accurate genome information. NGS method allows
the parallel sequencing of multiple DNA fragments. The aim of this work was
to implement the combination of multiplex ampliﬁcation assay with contemporary
massive parallel sequencing technology for molecular diagnostic application.
Methods: We evaluated Multiplex Ampliﬁcation of Speciﬁc Targets for
Resequencing (MASTR™, Multiplicon) assay for the analysis of the CFTR gene on
the Roche 454 GS Junior system sequencer, to identify disease-causing mutations
in cystic ﬁbrosis (CF) patiens. CF patient samples were analysed using the CFTR
MASTR assay ampliﬁed 35 amplicons (330–490 bp) of coding region of the CFTR
gene. The sequencing data were analysed with the software Sequence Pilot (SeqNext
module, JSI Medical Systems). A ﬁrst evaluation relied on the analysis of DNA
templates containing known variation to generate a control sample. Secondly, we
analysed CF patient samples with unknown CF patological genotype. In the initial
evaluation, all known heterozygous mutations were detected. The percentage of
mutant reads ranged from 40% to 60%. Special attention was given to sequencing
accuracy in homopolymers. We were able to reliably distinguish mutations from
noise through the analysis of the raw signal intensities in homopolymers.
Conclusion: This work presents an evaluation of NGS for use in diagnostics. We
anticipate that the technique would further improve, and would allow reducing the
costs per analysis and the turn-around time, to beneﬁt patients who undergo CFTR
molecular testing.
